文献速递妇科

IVA期宫颈癌膀胱受累患者的治疗与长期临床结局

Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement.
PubMed 文献 · Gynecol Oncol · 2023-12-01

本回顾性研究纳入2000至2020年在本机构接受根治性放疗的76例经活检或MRI证实膀胱黏膜受累的IVA期宫颈癌患者,中位随访76个月,中位总生存期35个月,2年和5年总生存率分别为53.6%和40.9%;单独外照射放疗与外照射联合近距离放疗的总生存期和无复发生存期无显著差异;当前吸烟是严重晚期毒性的强预测因素,膀胱阴道瘘2年发生率为24%、10年为32%。

要点

  • 中位总生存期35个月,2年和5年总生存率分别为53.6%和40.9%
  • 单独外照射放疗(18例)与外照射联合近距离放疗(49例)的总生存期和无复发生存期无显著差异
  • 严重晚期毒性2年发生率为14%、10年为17%,膀胱阴道瘘2年为24%、10年为32%

核心结论

  • IVA期宫颈癌患者即使仅接受外照射放疗也可获得长期生存,这些患者应密切随访晚期放疗相关毒性。

研究设计与样本

  • 回顾性分析前瞻性维护数据库,纳入2000至2020年在本机构接受根治性放疗(单独外照射放疗或外照射放疗联合近距离放疗,联合或不联合化疗)的76例经活检或MRI证实膀胱黏膜受累的IVA期宫颈癌患者。
  • 采用Kaplan-Meier模型估计无复发生存期和总生存期,采用比例风险模型识别与复发或生存相关的临床变量。
  • 对严重晚期毒性(3至5级,发生于随访6个月后)和膀胱阴道瘘进行竞争风险模型分析,以盆腔复发和死亡为竞争事件删失,采用Gray检验和二元逻辑回归比较潜在预测因素。

主要发现

  • 中位随访时间76个月(四分位距58-91)。
  • 中位总生存期35个月(范围18-未达到),2年和5年总生存率分别为53.6%和40.9%。
  • 接受单独外照射放疗(18例)与外照射放疗联合近距离放疗(49例)的患者总生存期和无复发生存期无显著差异。
  • 当前吸烟是严重晚期毒性的强预测因素,严重晚期毒性2年发生率为14%、10年发生率为17%。
  • 膀胱阴道瘘2年发生率为24%、10年发生率为32%。

关键数值与推荐

  • 严重晚期毒性定义为3至5级、发生于随访6个月后的毒性。
  • 中位总生存期35个月(范围18-未达到),2年和5年总生存率分别为53.6%和40.9%。
  • 单独外照射放疗组18例,外照射放疗联合近距离放疗组49例,两组总生存期和无复发生存期无显著差异。
  • 严重晚期毒性2年发生率为14%、10年发生率为17%;膀胱阴道瘘2年发生率为24%、10年发生率为32%。

临床怎么用

  • 作者认为IVA期宫颈癌患者即使仅接受外照射放疗也可获得长期生存,这些患者应密切随访晚期放疗相关毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the long-term outcomes of patients with stage IVA cervical cancer, a rare and deadly disease for which long-term toxicity data are scarce, to guide clinician counseling and survivorship support. METHODS: In a retrospective review of a prospectively maintained database, we identified 76 patients with stage IVA cervical cancer with biopsy- or MRI-proven bladder mucosal involvement who received definitive radiotherapy (external beam radiotherapy [EBRT] alone or EBRT plus brachytherapy) with or without chemotherapy at our institution between 2000 and 2020. We used Kaplan-Meier modeling to estimate recurrence-free survival (RFS) and overall survival (OS) and used proportional hazard modeling to identify clinical variables associated with recurrence or survival. We performed actuarial competing risk modeling for severe late toxicity (grades 3 to 5, occurring >6 months of follow-up) and vesicovaginal fistulae (VVF), censoring for pelvic recurrence and death, and made comparisons between potential predictors using Gray's test and binary logistic regression. RESULTS: The median follow-up time was 76 months (interquartile range 58-91). The median OS duration was 35 months (range, 18-not reached), and the 2- and 5-year OS rates were 53.6% and 40.9%, respectively. OS and RFS did not differ significantly between patients who received EBRT alone (N = 18) or EBRT plus brachytherapy (N = 49). Current smoking was a strong predictor of severe late toxicity, whose incidence was 14% at 2 years and 17% at 10 years. The VVF incidence was 24% at 2 years and 32% at 10 years. CONCLUSION: Patients with stage IVA cervical cancer, even those who receive EBRT alone, can have long-term survival. These patients should be followed closely for late radiation-related toxicity.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sammouri J, Venkatesan AM, Lin LL, et al. Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement. Gynecol Oncol. 2023. PMID: 38041900. doi:10.1016/j.ygyno.2023.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。